|Application ||WB, E|
|Calculated MW||157129 Da|
|Antigen Region||147-176 aa|
|Other Names||B-cell CLL/lymphoma 9-like protein, B-cell lymphoma 9-like protein, BCL9-like protein, Protein BCL9-2, BCL9L, DLNB11|
|Target/Specificity||This BCL9L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 147-176 amino acids from the N-terminal region of human BCL9L.|
|Precautions||BCL9L Antibody(N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).|
|Tissue Location||Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).
Miller, T.C., et al. J. Mol. Biol. 401(5):969-984(2010)
Fritzmann, J., et al. Gastroenterology 137(1):165-175(2009)
Olsen, J.V., et al. Cell 127(3):635-648(2006)
Sampietro, J., et al. Mol. Cell 24(2):293-300(2006)
Brembeck, F.H., et al. Genes Dev. 18(18):2225-2230(2004)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.